Microarray analysis of human leukemia cell lines revealed that three LQT-syndrome-related genes, KCNH2, SCN5A, and SNTA1, were differentially expressed in cells after treatment with reboxinib, showing a decrease in KCNH2 and an increase in SCN5A and SNTA1 (79). This evidence concerns the gene KCNH2 and leukemia.